Published in Lancet on June 11, 1994
Results of adjuvant interferon study in WHO melanoma programme. Lancet (1994) 1.62
Heredopathia atactica polyneuritiformis: Refsum's disease. Acta Neurol Scand (1985) 2.03
Heredopathia atactica polyneuritiformis (refsum's disease) treated by diet and plasma-exchange. Lancet (1979) 1.53
What is the optimal therapy of brain metastases? Clin Oncol (R Coll Radiol) (2001) 1.40
Sun beds and melanoma. Br Med J (Clin Res Ed) (1983) 1.04
In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer (1997) 0.92
Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol (2001) 0.90
Insulin abuse by a drug addict. Br Med J (1972) 0.84
Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs (2000) 0.83
Successful bone marrow transplant for Fanconi's anaemia. Br Med J (1977) 0.83
Cutaneous melanoma-associated retinopathy. Ophthalmology (1994) 0.81
Detection of tyrosinase mRNA by RT-PCR in the peripheral blood of patients with advanced metastatic melanoma. Melanoma Res (1999) 0.81
Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol (1979) 0.81
Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer (1983) 0.80
Agranulocytosis in breast-cancer patients treated with levamisole. Lancet (1978) 0.79
Sentinel-lymph-node biopsy. N Engl J Med (1999) 0.79
The CDKN2A tumour suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers. Melanoma Res (2002) 0.79
Metastasis to the penis from malignant melanoma: case report and review of the literature. Clin Oncol (R Coll Radiol) (1992) 0.79
Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. Br Med J (Clin Res Ed) (1984) 0.78
The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma. Anticancer Drugs (1996) 0.77
Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol (1992) 0.77
In vitro cytotoxicity of norviburtinal and isopinnatal from Kigelia pinnata against cancer cell lines. Planta Med (2000) 0.77
Malignant melanoma co-existing with sarcoidosis: implications for prognosis and management. Melanoma Res (1996) 0.76
Overexpression of HER-2 in thick melanoma. Melanoma Res (2002) 0.76
Update results of vindesine as a single agent in the therapy of advanced malignant melanoma. Cancer Treat Rev (1980) 0.75
Paraneoplastic eosinophilia in malignant melanoma. J R Soc Med (1993) 0.75
Adjuvant therapy of melanoma. Lancet (1998) 0.75
Prognostic factors in therapeutic lymphadenectomy in melanoma. Melanoma Res (2001) 0.75
Dissection of regional lymph nodes in cutaneous melanoma. Lancet (1998) 0.75
Symptom relief with levamisole in stage IV Hodgkin's disease. Br Med J (1977) 0.75
Pharmaceuticals from plants. Lancet (1994) 0.75
Adjuvant interferon alfa-2b for high-risk melanoma. J Clin Oncol (1996) 0.75
Lipophilicity of some substituted morpholine derivatives synthesized as potential antinociceptive agents. Arch Pharm (Weinheim) (1990) 0.75
Activity of platinum drugs against melanoma cell lines: is it modulated in vitro in the presence of tamoxifen? Anticancer Res (1995) 0.75
Malignant melanoma: prolonged survival after cerebral metastasis. J R Soc Med (1985) 0.75
Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines. Anticancer Res (1993) 0.75
Evaluation of S12363, a novel vinca alkaloid drug in the treatment of advanced malignant melanoma. A phase II study. Anticancer Res (1993) 0.75
Early or low-grade melanoma? Lancet (1987) 0.75
Medicine and the Olympic games of antiquity. Hist Med (1981) 0.75
Clinical results of bone marrow transplantation in aplasia. Report of Westminster Hospital bone marrow transplant team [proceedings]. Pathol Biol (Paris) (1978) 0.75
The effect of vindesine therapy on the in vitro immune response of patients with advanced malignant melanoma. Clin Oncol (1981) 0.75
Pigment streaks in the nail plate due to secondary malignant melanoma. Br J Dermatol (1983) 0.75
The treatment of advanced malignant melanoma. Practitioner (1980) 0.75
The importance of dose of thymosin for the in vitro induction of T-lymphocytes from patients with solid tumours. Clin Oncol (1978) 0.75
Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy. Cancer Treat Rev (1983) 0.75
Effect of the position of the cyano-group of cyanopregnenolones on their drug metabolic inducing activity. Eur J Drug Metab Pharmacokinet (1991) 0.75
Synthesis of 2-, 4- and 5-benzoylpyrrole-3-acetic acids and study of their in vitro effects on active oxygen species. Pharmazie (1990) 0.75
Fertility after prolonged chemotherapy for metastatic malignant disease. Lancet (1996) 0.75
Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy. Clin Oncol (R Coll Radiol) (1991) 0.75
Activity of extracts of Kigelia pinnata against melanoma and renal carcinoma cell lines. Planta Med (1994) 0.75